OncoMatch/Clinical Trials/NCT06756932
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
Is NCT06756932 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including BGB-21447 and Fulvestrant for hormone-receptor-positive breast cancer.
Treatment: BGB-21447 · Fulvestrant · BGB-43395 — This is a dose escalation and dose expansion study to assess the safety and tolerability of BGB-21447 (a B-cell leukemia/lymphoma 2 inhibitor, Bcl-2i) in combination with fulvestrant, with or without BGB-43395 (cyclin-dependent kinase 4 inhibitor, CDK4i), in adults with HR+/HER2- metastatic breast cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Endocrine / hormonal
Other
Cancer type
Breast Carcinoma
Biomarker criteria
Required: ESR1 hormone receptor positive
HR+
Required: HER2 (ERBB2) negative
HER2-
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: endocrine therapy — adjuvant or advanced/metastatic
including prior endocrine therapy
Must have received: CDK4/6 inhibitor — adjuvant or advanced/metastatic
including prior...CDK4/6 inhibitor in either the adjuvant or advanced/metastatic setting
Cannot have received: BCL2 inhibitor
Prior Bcl-2 inhibitor exposure
Cannot have received: CDK4 inhibitor
Exception: For triplet combination cohorts only
For triplet combination cohorts only: Prior therapy selectively targeting CDK4
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Hoag Memorial Presbyterian · Newport Beach, California
- University of Iowa Hospitals and Clinics · Iowa City, Iowa
- Md Anderson Cancer Center · Houston, Texas
- Fred Hutchinson Cancer Research Center · Seattle, Washington
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06756932 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior BCL2 inhibitor, CDK4 inhibitor disqualifies patients from enrollment.
Does this trial require ESR1?
Yes, ESR1 hormone receptor positive is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 negative is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages